Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH
NCT02502773Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Feb 2016
- Primary completion
- Jul 2018
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hetastarch in hypovolemia (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoints: Renal dysfunction at 14 days, Pulmonary complication at 14 days and 3 more. Started Feb 2016; status: completed.
02
Drugs
hetastarch
03
Conditions
hypovolemia
Beyond the preview
Go deeper on NCT02502773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502773.